Commercially available BJFF.6 healthy human fibroblasts were reprogrammed into iPSCs (NF1+/+) and were subsequently CRISPR/Cas9 engineered at the Washington University Genome Engineering and iPSC Core (GEiC) to harbor a heterozygous (NF1+/–) or homozygous (NF1–/–) NF1 mutation found in patients with NF1: 6619C>T, c.6513T>A, or c.2041C>T (20). hiPSCs were maintained in feeder-free, Matrigel-coated plates in mTeSR Plus medium (STEMCELL Technologies).

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.